Karyopharm Therapeutics (KPTI) Competitors $4.17 -0.07 (-1.75%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. LIMN, INKT, TIL, CRBU, NXTC, IPHA, LFVN, IMRX, ENTA, and SPROShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Liminatus Pharma (LIMN), MiNK Therapeutics (INKT), Instil Bio (TIL), Caribou Biosciences (CRBU), NextCure (NXTC), Innate Pharma (IPHA), Lifevantage (LFVN), Immuneering (IMRX), Enanta Pharmaceuticals (ENTA), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Liminatus Pharma MiNK Therapeutics Instil Bio Caribou Biosciences NextCure Innate Pharma Lifevantage Immuneering Enanta Pharmaceuticals Spero Therapeutics Liminatus Pharma (NASDAQ:LIMN) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Does the media refer more to LIMN or KPTI? In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Liminatus Pharma. MarketBeat recorded 7 mentions for Karyopharm Therapeutics and 2 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 0.94 beat Karyopharm Therapeutics' score of 0.22 indicating that Liminatus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Karyopharm Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer LIMN or KPTI? Karyopharm Therapeutics has a consensus target price of $37.40, indicating a potential upside of 797.74%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Do institutionals and insiders have more ownership in LIMN or KPTI? 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 2.8% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is LIMN or KPTI more profitable? Liminatus Pharma has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -43.99%. Company Net Margins Return on Equity Return on Assets Liminatus PharmaN/A N/A N/A Karyopharm Therapeutics -43.99%N/A -35.95% Which has higher valuation & earnings, LIMN or KPTI? Liminatus Pharma has higher earnings, but lower revenue than Karyopharm Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiminatus PharmaN/AN/AN/AN/AN/AKaryopharm Therapeutics$145.24M0.25-$76.42M-$13.26-0.31 SummaryKaryopharm Therapeutics beats Liminatus Pharma on 7 of the 10 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.07M$2.43B$5.56B$9.26BDividend YieldN/A1.79%4.23%4.03%P/E Ratio-0.319.1428.5819.56Price / Sales0.25711.83434.47183.65Price / CashN/A164.3436.0257.93Price / Book-0.194.658.165.58Net Income-$76.42M$30.99M$3.24B$257.82M7 Day Performance-13.39%-0.08%-0.64%-0.39%1 Month Performance-8.24%7.08%4.93%7.80%1 Year Performance-72.23%-6.56%26.04%12.95% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.9013 of 5 stars$4.17-1.7%$37.40+797.7%-70.8%$36.07M$145.24M-0.31380Analyst DowngradeLIMNLiminatus PharmaN/A$6.33-4.8%N/AN/A$164.68MN/A0.00N/AINKTMiNK Therapeutics2.5049 of 5 stars$40.61-36.7%$37.50-7.7%+145.7%$161.87MN/A-16.1230News CoverageAnalyst DowngradeHigh Trading VolumeTILInstil Bio3.4168 of 5 stars$24.49flat$119.00+385.9%+76.7%$160.65MN/A-2.05410Positive NewsCRBUCaribou Biosciences2.9088 of 5 stars$1.70+4.3%$8.50+400.0%-24.4%$158.11M$9.92M-1.05100Positive NewsGap UpNXTCNextCure4.3475 of 5 stars$4.90+3.4%$3.50-28.6%-76.2%$157.34MN/A-2.7890Analyst ForecastGap UpHigh Trading VolumeIPHAInnate Pharma2.6049 of 5 stars$1.70-2.5%$11.00+547.1%-16.5%$156.71M$21.77M0.00220Positive NewsLFVNLifevantage4.3467 of 5 stars$12.38+3.1%$30.50+146.4%+102.6%$155.86M$200.16M17.94260News CoveragePositive NewsIMRXImmuneering3.2597 of 5 stars$4.17-5.7%$13.25+217.7%+242.6%$150.06MN/A-2.1360ENTAEnanta Pharmaceuticals3.9191 of 5 stars$6.96+6.1%$18.00+158.6%-60.2%$148.81M$67.64M-1.53160News CoveragePositive NewsSPROSpero Therapeutics3.9004 of 5 stars$2.64-6.0%$5.00+89.4%+72.3%$147.60M$47.98M-2.06150Positive News Related Companies and Tools Related Companies Liminatus Pharma Competitors MiNK Therapeutics Competitors Instil Bio Competitors Caribou Biosciences Competitors NextCure Competitors Innate Pharma Competitors Lifevantage Competitors Immuneering Competitors Enanta Pharmaceuticals Competitors Spero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredCentral Banks Are Hoarding Gold – Should You?The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredAll New Social Security Numbers coming July 23?To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
